Subclassification of Type 2 Diabetes

The objective of the CCG is to characterize pathogenetic mechanisms in prediabetic at-risk subjects and biomarkers indicating progression to overt type 2 diabetes in these individuals. We will analyse metabolomic, proteomic and genetic marker profiles together with bioimaging (MRI/MRS) and metabolic tests to provide new insights into the pathways involved in the development of type 2 diabetes. As this is a heterogeneous disease in its clinical appearance, we also hypothesize that distinct pathogenic mechanisms lead to different subtypes of type 2 diabetes and that knowledge of these entities will allow individualized risk prediction and prevention.